Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211013 · ClinicalTrials.gov registry record · Early Phase 1
Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD
A Early Phase 1 study, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT03211013: Completed Early Phase 1 study, sponsored by Palo Alto Veterans Institute for Research.
NCT03211013 is a Early Phase 1 study that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 17 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03211013, a Early Phase 1 study, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The investigators will test whether intranasal oxytocin (24 IU vs placebo) will induce effects on attention bias and startle comparable to those the investigators have shown to be induced by the presence (vs absence) of a service dog in Veterans diagnosed with PTSD. This possibility is suggested by a 2015 study showing that urinary oxytocin levels are elevated in association with mutual gaze between dogs and their owners.
Primary Outcome
Changes between oxytocin vs. placebo lab sessions in the asymmetric allocation of visual attention to one or another of a pair of visual stimuli presented simultaneously as quantified by gaze tracking
Interventions
- DRUG Oxytocin
- DRUG Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2021-06-09 |
| Phase | Early Phase 1 |
What the finished NCT03211013 record still lists
NCT03211013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT03211013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03211013 about?
NCT03211013 is a clinical study titled "Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD". The investigators will test whether intranasal oxytocin (24 IU vs placebo) will induce effects on attention bias and startle comparable to those the investigators have shown to be induced by the presence (vs absence) of a service dog in Veterans diagnosed with PTSD. This possibility is suggested by ...
What is the current status of trial NCT03211013?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2017-07-10. Estimated completion is 2021-06-09.
What interventions are being tested in trial NCT03211013?
The interventions under investigation include: Oxytocin (DRUG), Placebos (DRUG).
Who is sponsoring clinical trial NCT03211013?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03211013's enrollment target sits among peer trials
17 1351st of 2000 higher than 632 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI